SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-127033
Filing Date
2024-11-14
Accepted
2024-11-14 16:05:25
Documents
53
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q inkt-20240930.htm   iXBRL 10-Q 1220145
2 EX-31.1 inkt-ex31_1.htm EX-31.1 15688
3 EX-31.2 inkt-ex31_2.htm EX-31.2 15652
4 EX-32.1 inkt-ex32_1.htm EX-32.1 10553
  Complete submission text file 0000950170-24-127033.txt   4653335

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inkt-20240930.xsd EX-101.SCH 774620
55 EXTRACTED XBRL INSTANCE DOCUMENT inkt-20240930_htm.xml XML 536367
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40908 | Film No.: 241461884
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)